Carzenide sodium

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 125913

CAS#: 6101-29-7 (sodium)

Description: Carzenide is an antispasmodic that has been used in the treatment of dysmenorrhoea. Currently Carzenide is an organic synthesis intermediate, used for synthetic drug.

Chemical Structure

img
Carzenide sodium
CAS# 6101-29-7 (sodium)
Instruction

Theoretical Analysis

MedKoo Cat#: 125913
Name: Carzenide sodium
CAS#: 6101-29-7 (sodium)
Chemical Formula: C7H6NNaO4S
Exact Mass: 222.99
Molecular Weight: 223.178
Elemental Analysis: C, 37.67; H, 2.71; N, 6.28; Na, 10.30; O, 28.67; S, 14.37

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 6101-29-7 (sodium)   138-41-0 (free base)  

Synonym: Carzenide sodium; Carzenide sodium salt; Sodium p-sulfamoylbenzoate; Carzenidum; Carzenida;

IUPAC/Chemical Name: sodium 4-sulfamoylbenzoate

InChi Key: FWOKISIYDJIISA-UHFFFAOYSA-M

InChi Code: InChI=1S/C7H7NO4S.Na/c8-13(11,12)6-3-1-5(2-4-6)7(9)10;/h1-4H,(H,9,10)(H2,8,11,12);/q;+1/p-1

SMILES Code: [Na+].NS(=O)(=O)C1=CC=C(C=C1)C([O-])=O

Appearance: To be determined

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 223.18 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Beyer J, Bierl A, Peters FT, Maurer HH. Screening procedure for detection of diuretics and uricosurics and/or their metabolites in human urine using gas chromatography-mass spectrometry after extractive methylation. Ther Drug Monit. 2005 Aug;27(4):509-20. doi: 10.1097/01.ftd.0000160719.96445.91. PMID: 16044110.

2: Shetnev A, Shlenev R, Efimova J, Ivanovskii S, Tarasov A, Petzer A, Petzer JP. 1,3,4-Oxadiazol-2-ylbenzenesulfonamides as privileged structures for the inhibition of monoamine oxidase B. Bioorg Med Chem Lett. 2019 Nov 1;29(21):126677. doi: 10.1016/j.bmcl.2019.126677. Epub 2019 Sep 10. PMID: 31537422.

3: Corcuera A, Stolle K, Hillmer S, Seitz S, Lee JY, Bartenschlager R, Birkmann A, Urban A. Novel non-heteroarylpyrimidine (HAP) capsid assembly modifiers have a different mode of action from HAPs in vitro. Antiviral Res. 2018 Oct;158:135-142. doi: 10.1016/j.antiviral.2018.07.011. Epub 2018 Jul 20. PMID: 30031759.

4: New bitter blocker discovered, study finds. J Am Dent Assoc. 2011 Aug;142(8):901. doi: 10.14219/jada.archive.2011.0291. PMID: 21919220.

5: Patil R, Fells JI, Szabó E, Lim KG, Norman DD, Balogh A, Patil S, Strobos J, Miller DD, Tigyi GJ. Design and synthesis of sulfamoyl benzoic acid analogues with subnanomolar agonist activity specific to the LPA2 receptor. J Med Chem. 2014 Aug 28;57(16):7136-40. doi: 10.1021/jm5007116. Epub 2014 Aug 12. PMID: 25100502; PMCID: PMC4148159.

6: Eckhardt K, King MT, Gocke E, Wild D. Mutagenicity study of Remsen-Fahlberg saccharin and contaminants. Toxicol Lett. 1980 Nov;7(1):51-60. doi: 10.1016/0378-4274(80)90085-5. PMID: 6794189.

7: Ullrich KJ, Fritzsch G, Rumrich G, David C. Polysubstrates: substances that interact with renal contraluminal PAH, sulfate, and NMeN transport: sulfamoyl-, sulfonylurea-, thiazide- and benzeneamino-carboxylate (nicotinate) compounds. J Pharmacol Exp Ther. 1994 May;269(2):684-92. PMID: 8182536.

8: Poncelet F, Mercier M, Lederer J. Saccharin: para forms of some impurities are not mutagenic in Salmonella typhimurium. Food Cosmet Toxicol. 1980 Aug;18(4):453. doi: 10.1016/0015-6264(80)90236-9. PMID: 7007186.

9: HAMOR GH, JANFAZA M. Synthesis of alkyl esters of 4-amino-2-sulfamoylbenzoic acid. J Pharm Sci. 1963 Jan;52:102-3. doi: 10.1002/jps.2600520126. PMID: 13952427.

10: Palfrey HC, Silva P, Epstein FH. Sensitivity of cAMP-stimulated salt secretion in shark rectal gland to "loop" diuretics. Am J Physiol. 1984 Mar;246(3 Pt 1):C242-6. doi: 10.1152/ajpcell.1984.246.3.C242. PMID: 6322593.